Shows / Lab to Lives
Lab to Lives
A simple question started this show: How do we medicine from the lab to making a difference in people's lives as quickly as possible?
The answers are complex. Actual solutions are hard to come by. We want to distill ideas until we see actual impact in the industry.
Our three hosts all have backgrounds in life sciences and in improv comedy. Together, with their guests, they're on a mission to have conversations that can have an impact. And have some fun along the way.
Episodes
Lab to LivesDecentralized Clinical Trials as Treatment Options with Ewa Lindqvist
Send us Fan Mail Ever imagined the immense potential that decentralized clinical trials (DCTs) could unlock for patients and sponsors? This week, we're going…
Lab to LivesExploring the Impact of Open Source Software on the Pharmaceutical Industry with Katja Glass
Send us Fan Mail Prepare to uncover the transformative potential of open source software in the pharmaceutical industry! Our distinguished guest, Katja Glass…
Lab to LivesThe Ethical and Legal Challenges in Unapproved Drug Access: A Talk with Patti Zettler
Send us Fan Mail Imagine being given a shot at a cure before it's even approved. That's the fascinating world of expanded access programs for unapproved…
Lab to LivesBridging the Gender Gap in Medical Research: The Potential of Wearable Technology
Send us Fan Mail Imagine you're on an eight-year journey trying to diagnose an autoimmune disease. Suzaan Sauerman, our insightful guest today, faced this…
Lab to LivesThe Hidden Factors Behind Executive Retention in Life Sciences
Send us Fan Mail Let's face it, executive turnover in the life sciences industry is a conundrum. Companies are offering competitive compensation, fostering…
Lab to LivesRavi Samavedam: On demand clean rooms for clinical trial supply
Send us Fan Mail This week we speak to Ravi Samavedam, Chief Innovation Officer for Azzur Group, about how on demand clean rooms can transform the business…
Lab to LivesLeif Kuse: Nudging the industry towards innovation with group purchasing for biotechs
Send us Fan Mail This week we speak to Leif Kuse, who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL. We speak about group…
Lab to LivesTirrell Payton: Transforming the mindset in Life Sciences from Punitive to Innovative
Send us Fan Mail This week we speak to Tirrell Payton, Managing Partner at Nooma Group Consulting, about mindset in life sciences. We speak about how there is…
Lab to LivesPhilip Russmeyer: Revolutionising clinical trials with true data anonymization
Send us Fan Mail This week we speak to Philip Russmeyer, Founder & CEO of Fitfile, about the promises that true data anonymization holds for transforming…
Lab to LivesSam Ewing: Virtual Wards & Digital Endpoints
Send us Fan Mail This week we host Sam Ewing, who is the Global Head of Pharma Partnerships at Doccla. We speak about endpoint development in general - and…
Lab to LivesChristian Born Djurhuus: Rethinking the waterfall approach of drug development
Send us Fan Mail This week we host Christian Born Djurhuus, who is a physician by training, a self-proclaimed geek and has had an impressive career in life…
Lab to LivesSimon Taylor: We need to deal with technological debt at clinical sites
Send us Fan Mail This week we speak to Simon Taylor, Head of European Solutions Consulting at Florence Healthcare. We focus on site oriented technology…
Lab to LivesOle Henriksen: How health technology assessments transformed clinical development
Send us Fan Mail This week we speak to Ole Henriksen, Associated Partner of Nordic Healthcare Group and pharmaceutical market access expert. We speak about how…
Lab to LivesKimberly Tableman: Does true transformation in trials start with the clinical protocol?
Send us Fan Mail This week we are hosting Kimberly Tableman, Founder and CEO of ESPERO Health, and speak about how clinical trial protocols are being…
Lab to LivesAndré Chagwedera: Patients should decide which research is funded
Send us Fan Mail This week we have André Chagwedera in the studio, the Founder and CEO of Fleming Protocol. We focus on health data, and what it would mean for…
Lab to LivesRaj Indupuri: Data is the currency of the life sciences industry
Send us Fan Mail We speak to Raj Indupuri, the co-founder & CEO of eClinical Solutions, about why data plays such a key role in our industry. And dispute this…
Lab to LivesLars Rosendal: Leadership as the differentiating factor when drug development is uncertain
Send us Fan Mail Today we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an…
Lab to LivesRebecca Godfrey: How does a specialist transform into a leader?
Send us Fan Mail In this episode we speak to Rebecca Godfrey, the author of The Leadership Vaccine, about transforming specialists into leaders. In The…
Lab to LivesSophia Zilber: Getting to quality research from patient registries
Send us Fan Mail Today is World Rare Disease day. It is only fitting that we speak to Sophia Zilber who is a statistical programmer, but also Board Member &…
Lab to LivesJohan Lauritsen: There needs to be a simple apply button to participate in a clinical trial
Send us Fan Mail We speak to Johan Lauritsen, CEO & Founder of Probe, about how clinical trials can be an alternative to treatment. Johan himself tried to…
Lab to LivesMaya Zlatanova: Setting the clinical trial up for success by listening to the healthcare ecosystem
Send us Fan Mail We speak to Maya Zlatanova, the CEO and Founder of Trialhub and FindMeCure about trial strategy for clinical trials. We speak about the amount…
Lab to LivesDr. Daniel Fox: Transforming the balance between sites and sponsors
Send us Fan Mail This week we speak to Dr. Daniel Fox, founder & CEO of Clinical Research Payment Network about how the power dynamic between sponsors and…
Lab to LivesBrian D Smith: Transforming the debate on drug pricing vs. innovation
Send us Fan Mail This week we speak to Brian D Smith, professor and author of a brand new book New Drugs, Fair Prices. In the book and on the show Brian…
Lab to LivesGraham Dutfield: As drugs become more precise, so needs the patent system
Send us Fan Mail We speak to Graham Dutfield, professor of International Governance and author of That High Design of Purest Gold on the evolution of IP…
Lab to LivesKristin Carlsson Petri: How pharmacometrics modelling can augment and replace clinical trials
Send us Fan Mail This week we dive into pharmacometrics as a discipline and the potential for replacing and augmenting clinical trials with modelling. We speak…
Lab to LivesTemitope Keyes: Digitizing clinical trials from paper to decentralized trials
Send us Fan Mail For this episode we explore the evolution of the collaboration and partnership structure between sponsors, CROs and technology vendors in life…
Lab to LivesDr. Elin Haf Davies: Benefits of designing trials for paediatric patients first
Send us Fan Mail We speak to Dr. Elin Haf Davies, CEO and founder of the technology company Apartito. We dive into the topic of designing trials with…
Lab to LivesAndreas Dam: Transforming how pharma engages with patients and HCPs
Send us Fan Mail Are pharmaceutical companies allowed to engage with patients and HCPs? Judging by how infrequent such interactions are, you might get the…
Lab to LivesAlexander Gray: Re-defining early-phase development to explore opportunities for assets
Send us Fan Mail The Life Science industry is both known for great leaps of innovation on the product side, and conservatism of process and practice on the…
Lab to LivesDr. Jack Pearson and Sofie Askervall: Digital contraception and data science-based clinical research
Send us Fan Mail We speak to Dr. Jack Pearson and Sofie Askervall from Natural Cycles about digital contraception and clinical trials based on data science. We…
Lab to LivesNechama Katan: Psychological safety as a prerequisite for solving wicked problems in life sciences
Send us Fan Mail In this episode Sam and Ivanna dive into the topic of wicked problem solving in life sciences with wicked problem wizard Nechama Katan. To…
Lab to LivesG.T. LaBorde: Arming clinicians with therapeutic options at the point of care
Send us Fan Mail We speak to G.T. LaBorde, the CEO of IllumiCare about clinical trial recruitment at the point of care. Patients want to participate in…
Lab to LivesSavva Kerdemelidis and Nicholas Fiorenza: Applying crypto to fund clinical research
Send us Fan Mail We speak to Savva Kerdemelidis and Nicholas Fiorenza, founders of Crowd Funded Cures about alternative financing models for clinical trials…
Lab to LivesAndy Yates: Taking cannabis down from the high to solve unmet medical needs
Send us Fan Mail Sam and Ivanna speak to Andy Yates, the Chief Scientific Officer for Artelo Biosciences about how they are tapping into the potential of the…
Lab to LivesJon I. Bergsteinsson on MDR: Separating the data haves from the have-nots
Send us Fan Mail Imagine if all pharmaceutical companies had to re-apply for approval of all existing drugs. Crazy as it seems, this is what is happening in…
Lab to LivesIvan Jarry: Transplanting the seamlessness of consumer health to clinical trials
Send us Fan Mail We speak to CEO of ObvioHealth, Ivan Jarry, about how clinical trials conducted for consumer products are different from trials in pharma and…
Lab to LivesMark Wheeldon: Accelerating reaction time to data trends
Send us Fan Mail Sam and Ivanna speak to Mark Wheeldon, the CEO of Formedix, about that there was once a time where sponsor companies would name their trial…
Lab to LivesBrian D Smith: Changing your DNA to pursue a novel business model
Send us Fan Mail Could a chimpanzee become a business school professor? He could, if you changed his DNA. In this episode we talk about how to change the DNA…
Lab to LivesPhilip Lyng Madsen: Re-thinking how patients can contribute to research
Send us Fan Mail After a successful career as a strategy consultant, Philip is attracted by the higher purpose of the life sciences space and takes on a quest…
Lab to LivesMatt Wilson: Transforming how patients benefit from population level research
Send us Fan Mail Matt Wilson guests the show and talks to Sam and Ivanna about how automating consent and recruitment processes can broaden the net in terms of…
Lab to LivesUlla Sofie Lønberg and Helle Hartnack on Bias: How behavioral trials can transform access to treatment
Send us Fan Mail “It is always fun to have some data that makes you go Wow! I didn’t know this!” We speak to Ulla Sofie Lønberg and Helle Hartnack about…
Lab to LivesJakob Juul Rasmussen: Zero cost technology - transforming how smaller companies oversee their assets
Send us Fan Mail Sam and Ivanna speak to Jakob Juul Rasmussen about the stubborn prevalence of paper in clinical trials, especially in small pharmaceutical and…
Lab to LivesWillie Muehlhausen: Transformation in patient reported outcomes (eCOA, ePRO and DCT)
Send us Fan Mail Sam and Ivanna speak to Willie Muehlhausen about how simplifying and automating patient reported outcomes is not so much complicated, as it is…
Lab to LivesAdam Walker: Transformation in clinical data sources
Send us Fan Mail Sam and Ivanna speak Adam Walker about the transformation in clinical data from his experience with CROs, sites and sponsors. Adam takes us…
Lab to LivesTransformation in science, data and roles
Send us Fan Mail Sam and Ivanna speak to Angela Slocum about the difficulty in quantifying the benefits of risk based monitoring when mostly you find no issues…